HMHanne Mariën

Hanne Mariën

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Hanne Mariën has a total of 15 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Changes in Metabolism as a Diagnostic Tool for Lung Cancer: Systematic Review

    by Hanne Mariën, Elien Derveaux, Karolien Vanhove, Peter Adriaensens, Michiel Thomeer, Liesbet Mesotten

    Lung cancer is the leading cause of cancer-related mortality worldwide, with five-year survival rates varying from 3–62%. Screening aims at early detection, but half of the patients are diagnosed in advanced stages, limiting therapeutic possibilities. Positron emission tomography-computed tomography (PET-CT) is an essential technique in lung cancer detection and staging, with a sensitivity reaching 96%. However, since elevated 18F-fluorodeoxyglucose (18F-FDG) uptake is not cancer-specific, PET-CT often fails to discriminate between malignant and non-malignant PET-positive hypermetabolic lesions, with a specificity of only 23%. Furthermore, discrimination between lung cancer types is still impossible without invasive procedures. High mortality and morbidity, low survival rates, and difficulties in early detection, staging, and typing of lung cancer motivate the search for biomarkers to improve the diagnostic process and life expectancy. Metabolomics has emerged as a valuable technique for these pitfalls. Over 150 metabolites have been associated with lung cancer, and several are consistent in their findings of alterations in specific metabolite concentrations. However, there is still more variability than consistency due to the lack of standardized patient cohorts and measurement protocols. This review summarizes the identified metabolic biomarkers for early diagnosis, staging, and typing and reinforces the need for biomarkers to predict disease progression and survival and to support treatment follow-up.


  • Open Access

    Unraveling the Rewired Metabolism in Lung Cancer Using Quantitative NMR Metabolomics

    by Karolien Vanhove, Elien Derveaux, Liesbet Mesotten, Michiel Thomeer, Maarten Criel, Hanne Mariën, Peter Adriaensens

    Lung cancer cells are well documented to rewire their metabolism and energy production networks to enable proliferation and survival in a nutrient-poor and hypoxic environment. Although metabolite profiling of blood plasma and tissue is still emerging in omics approaches, several techniques have shown potential in cancer diagnosis. In this paper, the authors describe the alterations in the metabolic phenotype of lung cancer patients. In addition, we focus on the metabolic cooperation between tumor cells and healthy tissue. Furthermore, the authors discuss how metabolomics could improve the management of lung cancer patients.


  • Open Access

    Validation of a new electrophysiological fetal heart rate monitor: comparison with cardiotocography

    by Quentin Noirhomme, Elisa Rossetti, Hanne Marien, Daimy Roebroek, Michiel Rooijakkers, Zoë Van Noppen, Inge Thijs, Byron Olson, Julien Penders, Wilfried Gyselears